Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Coherus Bio
(NQ:
CHRS
)
1.260
-0.290 (-18.71%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Coherus Bio
< Previous
1
2
3
4
5
6
7
8
9
Next >
CHRS Stock Earnings: Coherus BioSciences Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
CHRS stock results show that Coherus BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
August 01, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
June 30, 2024
Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to...
Via
Talk Markets
Recap: Coherus BioSciences Q4 Earnings
March 13, 2024
Via
Benzinga
Earnings Preview For Coherus BioSciences
March 12, 2024
Via
Benzinga
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
June 27, 2024
– Transaction aligns with Coherus’ strategic focus on oncology –
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
June 05, 2024
Former Global Controller of Merck & Co., Inc. Enhances Financial, Operational and Strategic Transformational Expertise
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
May 30, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
May 23, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
CHRS Stock Earnings: Coherus BioSciences Misses EPS, Misses Revenue for Q1 2024
May 09, 2024
CHRS stock results show that Coherus BioSciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
May 09, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
May 08, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
May 01, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
April 08, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Why Coherus Biosciences Stock Tumbled on Thursday
March 14, 2024
The company fell well short of expectations for its fourth quarter.
Via
The Motley Fool
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
March 13, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 13, 2024
March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Via
Benzinga
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
March 05, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Completes Divestiture of Ophthalmology Franchise
March 04, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
February 23, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
February 21, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Why Coherus BioSciences Stock Jumped Today
February 06, 2024
As promised, Coherus is using the proceeds of a recent divestiture to pay down debt and reduce interest expenses.
Via
The Motley Fool
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
February 05, 2024
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Why Coherus BioSciences Stock Is Sinking Today
January 23, 2024
The positive reaction to Coherus' sale of its ophthalmology franchise to Sandoz didn't last long.
Via
The Motley Fool
Why Coherus Biosciences Popped Today
January 22, 2024
Coherus is divesting its non-core ophthalmology franchise.
Via
The Motley Fool
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 22, 2024
Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.